Alnylam Centogene, Alnylam Pharmaceuticals Partner on Biomarker Study of Transthyretin Amyloidosis The study, called TRAMmoniTTR, will longitudinally monitor the clinical status of both symptomatic and asymptomatic participants with variants in the TTR gene. RNAi Drug for Acute Hepatic Porphyria The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria. Alnylam, 23andMe Partner on Free Family Testing Program for Hereditary ATTR Amyloidosis 23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits. Invitae, Alnylam to Provide Free Genetic Testing for Primary Hyperoxaluria Through the Alnylam Act program, patients suspected of having the rare disease or with a family history of the illness will receive testing at no cost. An RNAi Approval The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News. Apr 3, 2017 Invitae, Alnylam to Provide Free Genetic Testing for Rare Amyloidosis Condition Sep 29, 2015 Court Rules Against University of Utah in RNAi IP Inventor Dispute Feb 13, 2015 Alnylam Aims to Release Multi-program Clinical Data in 1H 2015 Premium Feb 2, 2015 Alnylam Starts Phase I/II Trial of Complement-mediated Disease Therapy Premium Jan 20, 2015 Alnylam Looks to Sell $450M in Common Stock Premium Jan 9, 2015 Alnylam, Isis Ink IP Licensing Deal Premium Dec 15, 2014 Alnylam Takes Aim at NASH, Diabetes as Part of a Return to Big Indications Premium Dec 12, 2014 Alnylam Begins Clinical Trials of ATTR, Hypercholesterolemia Drugs Premium Dec 10, 2014 Alnylam Releases Preliminary Phase I Data on Hemophilia Drug Premium Dec 10, 2014 Alnylam Files to Begin Human Trial of Complement-mediated Disease Drug Premium Dec 3, 2014 Alnylam Publishes Paper on Development of GalNAc Conjugate Delivery Technology Premium Nov 18, 2014 Dicerna to Use Tekmira LNPs for PH1 Rx amid Shift to Conjugates, New RNAi Triggers Premium Nov 17, 2014 Alnylam Releases Phase II Data on ATTR Drug, Views Adverse Events as Non-issue Premium Nov 11, 2014 Alnylam Adds Infectious Liver Disease Programs to Pipeline Premium Nov 6, 2014 Alnylam Aims Broadly with Hemophilia Drug, Advances HBV Program toward Clinic Premium Nov 6, 2014 IP Update: Recent Patents Awarded to Alnylam Pharmaceuticals, Marina Biotech, and More Premium Nov 6, 2014 Wall Street in October Proves Tumultuous for Four RNAi/microRNA Shops Premium Nov 6, 2014 Alnylam Completes Enrollment in Phase II Trial of ATTR Drug Premium Oct 30, 2014 Alnylam Files to Begin Phase I Trial of Hypercholesterolemia Drug Premium Oct 23, 2014 IP Update: Recent Patents Awarded to Devgen, Alnylam, Alcon, and More Premium Load More Breaking News Beckman Coulter, Invitae Partner to Develop NGS Library Prep Applications Sick Infants Profiled with WGS See Better Diagnosis, More Care Changes UC Santa Cruz Center for Live Cell Genomics Wins $13.5M NIH Grant Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development Canaccord Genuity Initiates Coverage of Pacific Biosciences With Buy Rating Alternative Genetic Counseling Approach Leads to Higher Patient Satisfaction, Study Suggests The Scan Highly Similar Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News. Gain of Oversight According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research. Lasker for mRNA Vaccine Work The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.